Jonathan Rowe

Principal, Head of R&D Quality, Operations and Risk Management at ZS

Jonathan's Session

[September 8, 2022]
8:45 AM EST
Theme: Compliance is Key: ICH E6 (R3) & E8 (R1) Guidance Update – Getting In Front of The New Regulations

About Jonathan:


Jonathan Rowe has more than 25 years of experience supporting pharmaceutical companies in the development of medical therapies from the clinical, operational and business perspectives. Currently, Jonathan holds the position of Principal, Head of R&D Quality, Operations and Risk Management at ZS. In this role he partners across the industry to design and implement advanced approaches to identifying and mitigating clinical development risk, and improving end-to-end process, study, site and vendor quality.  From 2014-2019 Jonathan was the Head of Clinical Development Quality Performance and Risk Management at Pfizer, where his responsibilities included monitoring, modeling and predicting the Pfizer GCP Quality Management System, leading the analysis of Pfizer’s Clinical Trial Quality Performance and ensuring clinical trial quality risk management is built into all trials. At Pfizer he has held a number of roles including Clinical Director, with responsibility for the Phase IIIb and IV Lipitor program; Director, Intellectual Property Strategy Management; and Senior Director of Process and Performance. Jonathan spent a number of years in “small pharma” as the Head of Intellectual Property and Portfolio Strategy for both Amarin and Dignity Sciences. Jonathan earned his Ph.D. and M.S. at the Albert Einstein College of Medicine and his M.A. from Binghamton University.